Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Replicate Bioscience Inc. is managing 2 pending office actions in the Chemistry & Materials technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution landscape. This spread suggests that the company's chemical innovations may span different technical sub-sectors within the broader materials science field.
SUN U KIM is identified as the busiest examiner for the company, currently managing 1 pending office action. This 1 busiest examiner pending action is among the total 2 pending office actions in the portfolio. Because the workload is split between 2 distinct examiners and 2 distinct art units, the company must navigate different examination styles and art unit standards simultaneously. This decentralized approach requires a more varied prosecution strategy compared to portfolios concentrated under 1 distinct examiner or 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SUN U | 1 | 78.2% | +11.6% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713901 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | CHESTNUT, BARRY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18731901 | SYSTEM AND METHOD FOR CARDIOPULMONARY BYPASS USING HYPOBARIC OXYGENATION | KIM, SUN U | — |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731901 | SYSTEM AND METHOD FOR CARDIOPULMONARY BYPASS USING HYPOBARIC OXYGENATION | KIM, SUN U | 1777 | §102§103DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18713901 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | CHESTNUT, BARRY A | 1672 | §101DP | Non-Final OA | — | Pending | May 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialReplicate Bioscience Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sun U Kim has the most, with 1 of Replicate Bioscience Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
